These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 21646519)

  • 21. Replication capacity of minority variants in viral populations can affect the assessment of resistance in HCV chimeric replicon phenotyping assays.
    Verbinnen T; Jacobs T; Vijgen L; Ceulemans H; Neyts J; Fanning G; Lenz O
    J Antimicrob Chemother; 2012 Oct; 67(10):2327-37. PubMed ID: 22723600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Replication of a novel subgenomic HCV genotype 1a replicon expressing a puromycin resistance gene in Huh-7 cells.
    Liang C; Rieder E; Hahm B; Jang SK; Paul A; Wimmer E
    Virology; 2005 Mar; 333(1):41-53. PubMed ID: 15708591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Searching for synergy: Identifying optimal antiviral combination therapy using Hepatitis C virus (HCV) agents in a replicon system.
    Pomeroy JJ; Drusano GL; Rodriquez JL; Brown AN
    Antiviral Res; 2017 Oct; 146():149-152. PubMed ID: 28882564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibitory effects of Pycnogenol® on hepatitis C virus replication.
    Ezzikouri S; Nishimura T; Kohara M; Benjelloun S; Kino Y; Inoue K; Matsumori A; Tsukiyama-Kohara K
    Antiviral Res; 2015 Jan; 113():93-102. PubMed ID: 25446333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selecting and characterizing drug-resistant hepatitis C virus replicon.
    Vliegen I; Delang L; Neyts J
    Methods Mol Biol; 2013; 1030():93-103. PubMed ID: 23821262
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interferon-alpha and ribavirin resistance of Huh7 cells transfected with HCV subgenomic replicon.
    Aus dem Siepen M; Oniangue-Ndza C; Wiese M; Ross S; Roggendorf M; Viazov S
    Virus Res; 2007 Apr; 125(1):109-13. PubMed ID: 17254660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
    Halfon P; Sarrazin C
    Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HCV Replicon Systems: Workhorses of Drug Discovery and Resistance.
    Khan S; Soni S; Veerapu NS
    Front Cell Infect Microbiol; 2020; 10():325. PubMed ID: 32714881
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus.
    Shimakami T; Welsch C; Yamane D; McGivern DR; Yi M; Zeuzem S; Lemon SM
    Gastroenterology; 2011 Feb; 140(2):667-75. PubMed ID: 21056040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
    Lenz O; Verbinnen T; Lin TI; Vijgen L; Cummings MD; Lindberg J; Berke JM; Dehertogh P; Fransen E; Scholliers A; Vermeiren K; Ivens T; Raboisson P; Edlund M; Storm S; Vrang L; de Kock H; Fanning GC; Simmen KA
    Antimicrob Agents Chemother; 2010 May; 54(5):1878-87. PubMed ID: 20176898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical significance of drug resistance-associated mutations in treatment of hepatitis C with direct-acting antiviral agents].
    Li Z; Chen ZW; Ren H; Hu P
    Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):170-174. PubMed ID: 28482402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.
    Tong X; Chase R; Skelton A; Chen T; Wright-Minogue J; Malcolm BA
    Antiviral Res; 2006 Jun; 70(2):28-38. PubMed ID: 16448708
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rational design of antiviral drug combinations based on equipotency using HCV subgenomic replicon as an in vitro model.
    Mandour M; Vliegen I; Paeshuyse J; Neyts J
    Antiviral Res; 2018 Jan; 149():150-153. PubMed ID: 29154807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis C Virus: Viral Quasispecies and Genotypes.
    Tsukiyama-Kohara K; Kohara M
    Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29271914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro.
    Mo H; Lu L; Pilot-Matias T; Pithawalla R; Mondal R; Masse S; Dekhtyar T; Ng T; Koev G; Stoll V; Stewart KD; Pratt J; Donner P; Rockway T; Maring C; Molla A
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4305-14. PubMed ID: 16189112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Replication of the subgenomic hepatitis C virus replicon in the presence of the NS3 protease inhibitors: a stochastic model].
    Ivanisenko NV; Mishchenko EL; Akberdin IR; Demenkov PS; Likhoshvai VA; Kozlov KN; Todorov DI; Samsonova MG; Samsonov AM; Kolchanov NA; Ivanisenko VA
    Biofizika; 2013; 58(5):758-74. PubMed ID: 25481944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Replication studies using genotype 1a subgenomic hepatitis C virus replicons.
    Gu B; Gates AT; Isken O; Behrens SE; Sarisky RT
    J Virol; 2003 May; 77(9):5352-9. PubMed ID: 12692237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Replicons of a Rodent Hepatitis C Model Virus Permit Selection of Highly Permissive Cells.
    Wolfisberg R; Holmbeck K; Nielsen L; Kapoor A; Rice CM; Bukh J; Scheel TKH
    J Virol; 2019 Oct; 93(19):. PubMed ID: 31292246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quasispecies dynamics and clinical significance of hepatitis C virus (HCV) antiviral resistance.
    Perales C
    Int J Antimicrob Agents; 2020 Jul; 56(1):105562. PubMed ID: 30315919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamic analysis of a serine protease inhibitor, MK-4519, against hepatitis C virus using a novel in vitro pharmacodynamic system.
    Brown AN; McSharry JJ; Adams JR; Kulawy R; Barnard RJ; Newhard W; Corbin A; Hazuda DJ; Louie A; Drusano GL
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1170-81. PubMed ID: 22155837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.